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Abstract: To investigate the global response of microvascular endothelial cells (MVECs) to foot-and-mouth (FMDV)
disease vaccine (FMDV) antigen and to explore the role of MVECs in FMD vaccine immunity, the gene expression
alterations of rat myocardium microvascular endothelial cells (RMMVECs) after stimulation with FMD virus (FMDV)
146S antigen were assayed using cDNA microarrays. We observed that 18 genes and 67 genes in RMMVECs were
respectively altered by FMDV 146S antigen at 6 h and 24 h, respectively. The former were all up-regulated genes, and
the latter included 60 up-regulated genes and 7 down-regulated genes. Among the differentially expressed genes, many
were associated to immune response, such as the genes encoding chemokines, interleukins, complement components,
and adhesion molecules. In particular, the chemokine genes had the greatest numbers and significant expression ratios.
A part of the altered genes with immune function was validated by real-time reverse transcription-PCR. The influence
of FMDV 146S antigen on the secretion of monocyte chemoattractant protein-1, interleukin-6 (IL-6), and IL-1 by
RMMVECs was confirmed by enzyme-linked immunosorbent assay, and the expression of vascular cell adhesion molecule-1 was identified by immunocytochemistry. The results indicated that the FMDV 146S antigen induces the changes
of immune-associated genes in RMMVECs, which suggests that MVECs play an important role in modulating how the
innate immune system responds to FMD vaccine.
Key words: Microvascular endothelial cells, foot-and-mouth disease virus, 146S, microarray

Introduction
Foot-and-mouth disease (FMD) is a severe and
highly contagious disease of cloven-hoofed animals
or humans, which is widely believed to be the most
economically devastating zoonosis in the world.
Vaccination is a routine practice for FMD control in
many countries, and the current FMD vaccines are
inactivated whole-virus preparations, whose essential

immunogenic component is FMD virus (FMDV) 146S
particles (1). An important fact is that vaccination can
protect animals, but the level of immune protection
can wane such that animals need revaccinating after 6
months (2). The multiple serotypes of FMDV with no
cross-protection between serotypes and the antigenic
variability make the control of FMD by vaccination
difficult. Although a great deal of knowledge about
FMD has been obtained in the last 100 years, the goal
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of life-long immunity to FMDV antigens is still far
from achievement. Most of the studies have focused
on antigen sites of FMDV and immune responses
to FMDV antigens of traditional immune cell, such
as T or B cells. However, many new viewpoints and
contents have already been added to the immunology
field. For example, microvascular endothelial cells
(MVECs) have been increasingly documented to be
important immune cells (3).
The microvascular endothelium is a highly
specialized cellular system lining capillary vessels
everywhere in bodies and occupying strategic
anatomical positions. MVECs play pivotal roles
in physiological processes such as vascular
homeostasis, nutrient delivery, and immune
trafficking (4), and in pathological processes
such as inflammation (5). The immune functions
of MVECs particularly attract more and more
attention for their critical intervention in leukocyte
recruitment, lymphocyte homing, and leukocyte
activation (6). Hemorrhage and inflammation in
gut mucosal tissues and cardiac tissues, which are
the typical pathological changes in FMDV-infected
animals (7), and the expression of FMDV receptors
in MVECs (8,9) suggest that there is a close relation
between FMDV and MVECs. However, what
changes of gene expression of MVECs the FMDV
antigen could cause has not been reported.
This study aimed to investigate the global
response of MVECs to FMD vaccine antigen
and explore the role of MVECs in the immunity
of FMD vaccines. Microarray technology is a
high throughput method that provides a useful
tool for identifying the repertoire change of
mRNA levels in cells in responses to a given
stimulus. Considering the availability of the rat
microarray and the susceptivity of rat to FMDV
(10), we used cDNA microarray to analyze gene
expression changes in cultured rat myocardium
microvascular endothelial cells (RMMVECs)
after exposure to FMDV 146S antigen, and we
confirmed part of the gene expression changes by
real-time reverse transcription-PCR (RT-PCR),
enzyme-linked immunosorbent assay (ELISA),
and immunocytochemical staining.
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Materials and methods
FMDV 146S antigen
BHK-21 cell cultures infected with the FMDV O/
China99 strain were kindly gifted by the Lanzhou
Veterinary Research Institute of the Chinese Academy
of Agricultural Science (Lanzhou, China). The cell
cultures with complete pathological change were
collected and inactivated with binary ethylene imine
(BEI). The FMDV 146S antigen was purified with
PEG-6000 as described previously (11). The purified
FMDV 146S particles were deeply stained with 1%
uranyl acetate and observed by transmission electron
microscope (TEM). The FMDV 146S particles were
homogeneous, round, black-staining bodies by TEM,
whose edges were smooth and whose diameters
were about 25 nm (data not shown). After being
quantitated by Bradford assay (12), the FMDV 146S
antigen was stored at -20 °C.
Cell culture and stimulation with FMDV 146S
antigen
The culture of RMMVECs was prepared as
described by Nishida et al. (13) with modification.
Briefly, Sprague-Dawley rats (15 days old) were
anesthetized with pentobarbital sodium (30 mg/kg)
by intraperitoneal injection and then heparinized
with heparin sodium (1000 U/kg, i.m.). Hearts
were rapidly excised and washed in ice-cold Hank’s
balanced salt solution (HBSS, Sigma, USA). After
removal of connective tissue, the atria, right ventricle,
and all valvular tissues, the left ventricular tissue was
opened and immersed in 70% ethanol for 30 s. The
epicardial and endocardial surfaces were removed,
and the remaining left ventricle tissue was minced
and digested with 0.2% collagenase II (Gibco, USA)
and with 0.02% trypsin (Sigma, USA) respectively for
20 min at 37 °C. The digested solution was filtered
through a 100-μm mesh filter, and the filtrate was
centrifuged at 1000 rpm for 10 min. Cells were
resuspended in DMEM (Gibco, USA) supplemented
with 20% fetal bovine serum (FBS, PAA, Austria),
2 mmol/L of L-glutamine, 100 IU/mL of penicillin,
and 100 μg/mL of streptomycin at a concentration of
1 × 105 cells/mL, and plated in 12-well culture plates
(Corning, USA) with 1 mL per well. After being
cultured in a humidified atmosphere with 5% CO2 at
37 °C for 2 h, attached cells were washed twice with
DMEM to allow differential adhesion and cultured
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in DMEM with 20% FBS, which was changed every
3 days. The confluent cells showed a cobblestone-like
or polygonal appearance, and they were subcultured
and identified by the positive immunofluorescent
staining for CD31 (data not shown). All experiments
were performed using second- to third-passage
RMMVECs.
For microarray and quantitative RT-PCR analysis,
cells were plated in 6-well plates at a density of 3 × 105
cells per well and cultured for 48 h, and the medium
was replaced with maintenance medium (DMEM
containing 2% FBS) overnight. Cells were then
incubated in maintenance medium with or without 20
μg/mL of the FMDV 146S antigen. After 6 h and 24 h
of stimulation, the medium was removed and washed
twice with PBS, and the total RNA was isolated and
processed as below. For ELISA, cells were seeded in
48-well plates for 48 h, and the subconfluent cells
were incubated overnight in maintenance medium.
Maintenance medium respectively containing 0.8,
4.0, and 20.0 μg/mL of the FMDV 146S antigen
was used, and the control cells were incubated in
maintenance medium without FMDV 146S antigen.
The supernatants in triplicate were collected after
3, 6, 12, 24, 48, and 72 h incubation, respectively.
For immunocytochemical staining, cells were
subcultured on chamber slips in a 24-well plate. After
incubation with or without 20.0 μg/mL of 146S for 24
h, the cells on slips were rinsed twice with PBS and
fixed in 95% ethanol for 15 min at -20 °C.
DNA microarray and data analysis
According to the methods previously described
(14), microarray analysis was carried out using 27K
rat genome-wide oligonucleotide microarrays at
CapitalBio Corporation (Beijing, China). Briefly,
a Rattus norvegicus genome oligonucleotide set
(version 3.0.5), consisting of 26,962 5’ amino acidmodified 70-mer probes representing 22,012 genes
and 27,044 gene transcripts, was purchased (Operon,
USA) and printed on silanized glass slides using a
SmartArrayTM microarrayer (CapitalBio Corp.). Total
cellular RNA was extracted with TRIzol (Invitrogen,
USA) from FDMV 146S-treated and control
RMMVECs. After being purified with NucleoSpin®
RNA clean-up (Macherey-Nagel, Germany) and
validated qualitatively with a denatured agarose gel
containing formaldehyde, 5 μg of DNase-treated

total RNA was prepared, and fluorescent dye (Cy5and Cy3-dCTP)-labeled cDNA, produced through
Eberwine’s linear RNA amplification method (15) and
subsequent enzymatic reaction, was then hybridized
to an array at 42 °C overnight. Finally, arrays were
scanned with a dual channel confocal LuxScanTM
scanner (CapitalBio Corp.), and the obtained images
were analyzed with LuxScan 3.0 (CapitalBio Corp.).
A space- and intensity-dependent normalization
based on a Lowess program was employed (16).
Genes with the signal intensity (Cy3 or Cy5) > 800
were regarded as the expressed ones. For each test
and control sample, 2 hybridizations were performed
by using a reversal fluorescent strategy. Only genes
whose alteration tendency kept consistent in both
microarrays and whose mean expression ratios
averaged above 2-fold were selected as differentially
expressed genes.
Quantitative RT-PCR
To validate the microarray results, quantitative
reverse transcription-PCR (qRT-PCR) was performed
to analyze representative genes using the LightCycler
FastStart DNA Master SYBR Green I PCR kit (Roche,
Switzerland) in a Roche LightCycler 1.2 real-time
PCR system according to the operator’s manual. A
total of 5 μg of RNAs extracted from each sample was
digested with RNase-free DNase I (Promega, USA)
and reverse transcribed into cDNA using Superscript
II reverse transcriptase (Invitrogen, USA). The
reaction was taken in a 20 μL final volume following
the manufacturer’s instructions. The reaction mix
contained 4 μL of first strand buffer (5×), 1 μL of
dNTPs mix (2.5 mM each), 2 μL of oligo-dT15
primer (1 μg, Promega), 1 μL of RNase inhibitor (40
U/μL, Promega), 2 μL of DTT (0.1 M, Invitrogen), 1.5
μL of superscript II reverse transcriptase (200 U/μL,
Invitrogen), 2.5 μg of template RNA, and RNase-free
water. The real-time RT-PCR reactions in triplicate
were carried out in a 20 μL final volume with the
LightCycler FastStart DNA Master SYBR Green I Kit
(Roche, Switzerland) using 1 μL of cDNA solution,
and using sequence-specific oligonucleotide primers
designed to yield approximately 200-bp sequences.
All primers (Table 1) used in this study were
designed with Primer Premier 5.0 software (Premier,
Canada) and synthesized by Invitrogen. In detail,
the master-mix for each PCR run was prepared as
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Table 1. Primers and amplification size for RT-PCR analysis.
Gene name

Reference sequence

Pla2g2a

NM_031598

Cxcl2

NM_053647

Il6

NM_012589

Ccl2

NM_031530

Il1a

NM_017019

Vcam1

NM_012889

Tgfb3

NM_013174

GAPDH

Primer type
Forward

TACCACCATCCCATCCAAGA

Reverse

GTGCCACATCCACGTTTCTC

Forward

TCAATGCCTGACGACCCTAC

Reverse

CAGTTAGCCTTGCCTTTGTTC

Forward

GGATACCACCCACAACAGACC

Reverse

AACGGAACTCCAGAAGACCAG

Forward

GTCGGCTGGAGAACTACAAGA

Reverse

TGCTGAAGTCCTTAGGGTTGA

Forward

AGGTGGTCAGTTAGATGCAGTG

Reverse

TTCTTCCCGTCTTTAGATGGTT

Forward

ACAGCTAAAGAACGGGGAACT

Reverse

TCTTTGACGCTCTTAGATGGG

Forward

TCAGTTTACCAAGCCAAAGTCC

Reverse

GAAGGTGTCTAGCCAAATGTCC

Forward

TGCTGAGTATGTCGTGGAG

Reverse

GTCTTCTGAGTGGCAGTGAT

follows: 13.8 μL of water, 1.6 μL of MgCl2 (3 mM),
0.8 μL of each primer (10 mM), 2 μL of FastStart
DNA Master SYBR Green I, and 1 μL of reverse
transcripts. The real-time RT-PCR cycles were as
follows: initiation with a 10-min denaturation at 95
°C, followed by 40 cycles of amplification with 15 s
of denaturation at 95 °C, 5 s of annealing according
to the melting temperatures of each pair of primers,
15 s of extension at 72 °C, and reading of the plate
for fluorescence data collection at 76 °C. To check
the specificity of the amplified product, melting
curve analyses were carried out at 75-95 °C, and 1.5%
agarose gel electrophoresis was conducted. A reaction
containing no reverse transcribed total RNA samples
was processed to demonstrate the absence of genomic
DNA contamination. The comparative threshold
cycle (CT) method was used for the calculation of
amplification fold. The expression level of each gene
was normalized by dividing by the expression level of
the “housekeeping” gene transcript.
Cytokine assay by ELISA
Chemokines and interleukins, which were
differentially expressed in FMDV 146S antigenstimulated RMMVECs, are important factors
regulating the migration and activation of
lymphocytes. To further characterize the translational
24

Primer sequence (5’-3’)

Amplicon size
276
195
254
203
260
201
284
288

level changes of interest genes, concentrations
of monocyte chemoattractant protein-1 (MCP1), interleukin-6 (IL-6), and IL-1β in cell culture
supernatants were determined using commercially
available ELISA kits (MCP-1 kit purchased from
BioSource, USA; IL-6 kit and IL-1β kit purchased
from Boster, China) according to manufacturer’s
instructions. Experiments for ELISA measurements
were done in triplicate wells from each preparation.
Results were expressed as mean ± standard errors of
the means.
All statistical analyses of variance used Student’s
t-test. Differences in the data were considered
significant or extremely significant at P values of less
than 0.05 or 0.01.
Immunocytochemistry
Vascular cell adhesion molecule-1 (VCAM-1) was
another important factor in immune response and
inflammation whose gene expression was changed
in FMDV 146S antigen-stimulated RMMVECs.
Immunocytochemical staining with the streptavidinperoxidase (SP) method was done to analyze the
expression of VCAM-1 in RMMVECs after exposure
to the FMDV 146S antigen. Briefly, fixed cells as
described above were blocked respectively with 3%
H2O2 for 10 min and 10% normal goat serum for
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20 min at room temperature (RT), the slides were
successively incubated with rabbit anti-rat VCAM-1
antibody (Zsbio, China) at a 1:100 dilution overnight
at 4 °C, and goat anti-rabbit IgG was conjugated with
biotin for 60 min at RT. For a negative control, the
anti-rat VCAM-1 antibody was replaced with PBS.
Following a 30-min incubation with streptavidinperoxidase, the slides were stained with DAB solution
for 5 min at RT. They were washed 3 times with 0.01
M PBS for 3 min each before each reagent, except the
primary antibody, was added. Finally, the slips were
mounted with gelatin and photomicrographs were
taken by light microscopy.

Results
Expression profile of RMMVECs stimulated
with FMDV 146S antigen
Rat 27K genome microarrays were used to
investigate the responses of RMMVECs to FMDV
146S antigen. This cDNA-based microarray platform
covers approximately 27,000 gene transcripts. The
microarray analysis revealed that 18 genes were
up-regulated in FMDV 146S antigen-stimulated
RMMVECs at 6 h (Table 2), and 60 genes were
up-regulated and 7 genes were down-regulated
at 24 h (Table 3). The expression alteration of

Table 2. Differentially expressed genes in RMMVECs stimulated with FDMV 146S antigen for 6 h.a
Category and
gene name

Gene ID number

Description

Relative mRNA
expression ratiob

Colony-stimulating factors
Csf3

ENSRNOG00000008525

Granulocyte colony-stimulating factor 3

3.76

Csf2

ENSRNOG00000026805

Granulocyte-macrophage colony-stimulating factor

2.77

Chemokines
Cxcl1

ENSRNOG00000002802

Growth regulated protein precursor (CXCL1)

3.49

LOC60665

ENSRNOG00000002843

CXC chemokine LIX (CXCL5)

2.99

Ccl20

ENSRNOG00000015992

Macrophage inflammatory protein-3-alpha (CCL20)

2.84

Cxcl2

ENSRNOG00000002792

Macrophage inflammatory protein-2 (CXCL2)

2.71

Rn30026248

ENSRNOG00000028043

Macrophage inflammatory protein-2-beta (CXCL3)

2.56

Cx3cl1

ENSRNOG00000016326

Chemokine (C-X3-C motif) ligand 1

2.01

Il19

ENSRNOG00000025571

Interleukin-19

2.30

Il6

ENSRNOG00000010278

Interleukin-6

2.25

Angptl4

ENSRNOG00000007545

Angiopoietin-like protein 4

2.44

Pla2g2a

ENSRNOG00000016945

Phospholipase A2

2.35

Ptx3

ENSRNOG00000012280

Pentaxin-related gene

2.31

Interleukins

Others

RGD1306776

ENSRNOG00000009131

Similar to hypothetical protein mgc41320

2.30

Cyp7b1

ENSRNOG00000009730

Cytochrome p450 7b1

2.13

Rn30012520

ENSRNOG00000013621

Rho family GTPase 1

2.12

Ppap2b

ENSRNOG00000008116

ER transmembrane protein Dri 42

2.04

Lcn2

ENSRNOG00000013973

Lipocalin 2

2.04

a

Total RNA was extracted from RMMVECs stimulated with 20 μg/mL of FMDV 146S antigen for 6 h and analyzed using microarray as
described in the Materials and Methods section. Control RMMVECs were incubated in culture medium without FMDV 146S antigen.
Genes whose expression in FMDV 146S antigen-stimulated RMMVECs was at least 2-fold higher than that of control RMMVECs were
listed.
b
Ratio of mRNA expression in FMDV 146S antigen-stimulated RMMVECs to that in control RMMVECs.
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Table 3. Differentially expressed genes in RMMVECs stimulated with FDMV 146S antigen for 24 h.a
Category and
gene name
Up-regulated genes
Chemokines
Rn30026248
LOC60665
Ccl3
Ccl20
Cxcl1
Ccl12_predicted
Cxcl2
Ccl2
Rn30000167
Ccl4
Interleukins
Il1b
Il6
Il1a
Complement component
C3
C6
C1s
Adhesion molecule
Vcam1
Metallothionein
Mt1a
Mt1a
Rn30017416
Mt1a
Mmp9
Enzymes
Pla2g2a
Enpp2
Npy
Sod2
Slpi
Jak2
Jak2
Rn30014253
Irak3
Hpx
Ptges
LOC171516
Xdh
Adamts5
Hsd11b1
Serping1
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Gene ID number

Description

Relative mRNA
expression ratiob

ENSRNOG00000028043
ENSRNOG00000002843
ENSRNOG00000011205
ENSRNOG00000015992
ENSRNOG00000002802
ENSRNOG00000000239
ENSRNOG00000002792
ENSRNOG00000007159
ENSRNOG00000000239
ENSRNOG00000011406

Macrophage inflammatory protein-2-beta
CXC chemokine LIX
Macrophage inflammatory protein-1-alpha
Macrophage inflammatory protein-3-alpha
Growth-regulated oncogene alpha
Monocyte chemoattractant protein-3
Macrophage inflammatory protein-2
Monocyte chemoattractant protein-1
Monocyte chemoattractant protein-3
Macrophage inflammatory protein-1-beta

4.65
4.58
3.09
2.78
2.71
2.51
2.32
2.24
2.16
2.08

ENSRNOG00000004649
ENSRNOG00000010278
ENSRNOG00000004575

Interleukin-1 beta
Interleukin-6
Interleukin-1 alpha

3.62
3.22
2.54

ENSRNOG00000019505
ENSRNOG00000024115
ENSRNOG00000011971

Complement component 3
Complement component 6
Complement component 1

2.61
2.45
2.04

ENSRNOG00000014333

Vascular cell adhesion molecule 1

3.02

ENSRNOG00000027838
ENSRNOG00000018756
ENSRNOG00000018926
ENSRNOG00000018756
ENSRNOG00000017539

Metallothionein
Metallothionein-i
Metallothionein-ii
Metallothionein-i
Matrix metalloproteinase-9

4.53
4.35
3.68
3.46
2.44

ENSRNOG00000016945
ENSRNOG00000004089
ENSRNOG00000009768
ENSRNOG00000019048
ENSRNOG00000013880
ENSRNOG00000015547
ENSRNOG00000015547
ENSRNOG00000015547
ENSRNOG00000004226
ENSRNOG00000018257
ENSRNOG00000006320
ENSRNOG00000017531
ENSRNOG00000007081
ENSRNOG00000001606
ENSRNOG00000005861
ENSRNOG00000007457

Phospholipase A2
Phosphodiesterase 2
Neuropeptide y precursor
Superoxide dismutase
Secretory leukocyte protease inhibitor
Tyrosine-protein kinase jak2
Tyrosine-protein kinase jak2
Tyrosine-protein kinase jak2
Interleukin-1 receptor-associated kinase 3
Hemopexin
Prostaglandin E synthase
20 alpha-hydroxysteroid dehydrogenase
Xanthine oxidoreductase
Aggrecanase-2
Hydroxysteroid 11-beta dehydrogenase 1
Serine (or cysteine) proteinase inhibitor

11.35
4.91
4.78
3.93
3.19
2.86
2.86
2.77
2.66
2.52
2.45
2.22
2.08
2.08
2.05
2.01
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Table 3. (Continued).
Category and
gene name

Gene ID number

Description

Relative mRNA
expression ratiob

Others
Lcn2

ENSRNOG00000013973

Lipocalin 2

5.63

Rn30023225

ENSRNOG00000024905

Similar to hypothetical protein

5.14

Sfrp2

ENSRNOG00000009465

Putative secreted frizzled-related protein

4.84

c

4.52

Rn30020678

ENSRNOG00000022362

-

Bf

ENSRNOG00000000419

B-factor, properdin

4.39

Hp

ENSRNOG00000014964

Haptoglobin precursor

4.25

Igfbp3

ENSRNOG00000008645

Insulin-like growth factor binding protein 3

3.15

Lnx1

ENSRNOG00000002272

Ligand of numb-protein X 1

2.84

Chi3l1

ENSRNOG00000003312

Glycoprotein-39

2.78

Ptx3

ENSRNOG00000012280

-

2.70

Tlr2

ENSRNOG00000009822

Toll-like receptor 2

2.58

Rn30009092

ENSRNOG00000009919

Similar to immune-responsive gene 1

2.54

Rn30018064

ENSRNOG00000019622

-

2.46

Rn30000470

ENSRNOG00000000569

-

2.36

Rn30018372

ENSRNOG00000019951

EGF-like module

2.24

Rn30024903

ENSRNOG00000026647

-

2.18

Rn30019109

ENSRNOG00000020733

Cathelicidin

2.17

RGD1309846

ENSRNOG00000026923

Similar to RIKEN cDNA 2010012F05

2.11

Bcl2a1

ENSRNOG00000013001

-

2.09

Map3k8

ENSRNOG00000016378

Tumor progression locus 2

2.08

RGD1309846

ENSRNOG00000017245

Similar to RIKEN cDNA 2010012F05

2.05

RSB-11-77

ENSRNOG00000016210

Rsb-11-77 protein

2.01

Ankrd1

ENSRNOG00000018598

Cardiac ankyrin repeat protein

0.47

Tpm1

ENSRNOG00000018184

Tropomyosin 1 alpha

0.45

Adarb1

ENSRNOG00000001227

Adenosine deaminase

0.45

Tgfb3

ENSRNOG00000009867

Transforming growth factor beta 3

0.44

Rn30022350

ENSRNOG00000024041

-

0.44

Fndc1

ENSRNOG00000018979

Fibronectin type III domain containing 1

0.42

Eln

ENSRNOG00000001469

Elastin

0.41

Down-regulated genes

a
Total RNA was extracted from RMMVECs stimulated with 20 μg/mL of FMDV 146S antigen for 24 h and analyzed using microarray as described in
the Materials and Methods section. Control RMMVECs were incubated in culture medium without FMDV 146S antigen. Genes whose expression in
FMDV 146S antigen-stimulated RMMVECs was at least 2-fold higher than that of control RMMVECs were listed.
b
Ratio of mRNA expression in FMDV 146S antigen-stimulated RMMVECs to that in control RMMVECs.
c
No description in the relative database.
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gene belonged to the CC subgroup. The 4 genes of
the CXC subgroup were still significantly altered at
24 h; however, more genes of the CC subgroup were
up-regulated, which included CCL2, CCL3, CCL4,
CCL7, CCL12, and CCL20.

genes encoding chemokines and interleukins was
significantly induced by FMDV 146S for 6 h and 24
h. Colony-stimulating factor (CSF) gene expression
was up-regulated only at 6 h, while the expression
of genes encoding complement components,
metallothioneins, and adhesion molecules (AM)
was up-regulated at 24 h. Among the differentially
expressed genes, many are involved in immune
response, including the up-regulated genes of
chemokines, interleukins, complement components,
CSF, and AM, and the down-regulated transforming
growth (TGF). Particularly, the chemokine genes
had the greatest number and the most significantly
up-regulated ratios. Interestingly, the subgroups
of up-regulated chemokine genes were different in
RMMVECs stimulated with FMDV 146S antigen
for different times. At 6 h, 4 chemokine genes
belonged to the CXC subgroup, including CXCL1,
CXCL2, CXCL3, and CXCL5, and only the CCL20

Validation of cDNA microarray data using qRTPCR
By real-time quantitative RT-PCR, the expression
of 3 genes was determined at 6 h, and the expression of
7 genes was determined at 24 h. RNAs from samples
and controls were extracted as described above. QRTPCR analysis confirmed the alteration of these genes
related with immune response or inflammatory
reaction, whose expression ratios were in agreement
with those by microarray analysis (Table 4). The
specificity of quantitative RT-PCR products was
identified with a melting curve showing a single peak
and 1.5% native agarose gel electrophoresis showing
a single specific band (data not shown).

Table 4. Quantitative RT-PCR confirmation of representative genes from microarray
analysis.a
Expression ratio
Gene name

6h
b

24 h
c

qRT-PCR

Microarray

qRT-PCR

Microarray

Pla2g2a

3.42

2.35

15.99

11.35

Cxcl2

3.04

2.71

5.33

4.65

Il6

2.21

2.25

1.66

3.22

d

NT

1.48

2.24

Ccl2 (Mcp-1)

NT

Il1a

NT

NT

2.58

2.54

Mt1a

NT

NT

8.22

3.46

Vcam1

NT

NT

2.15

3.02

Tgfb3

NT

NT

0.35

0.44

a

Total RNA was extracted from RMMVECs stimulated with 20 μg/mL of FMDV 146S
antigen for 24 h and analyzed using qRT-PCR as described in the Materials and Methods
section. Control RMMVECs were incubated in culture medium without FMDV 146S
antigen.
b

Expression ratios of qRT-PCR were calculated by the relative expression abundance
compared with the internal control (GAPDH) in FMDV 146S antigen-stimulated
RMMVECs to that in control RMMVECs.
c

The ratios in microarray analysis.

d
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Figure 1. MCP-1 (CCL2), IL-6, and IL-1β production by RMMVECs in response to FMDV 146S antigen. Different doses of FMDV
146S antigen were respectively added to the RMMVEC culture medium and incubated respectively for 3, 6, 12, 24, 48, and
72 h. Supernatants were collected in triplicate for ELISA analysis. Blank control RMMVECs were incubated in culture media
without FMDV 146S antigen. Representative findings are shown as mean and SDs from 3 independent experiments.
* P < 0.05, ** P < 0.01 (compared with control), # P < 0.05, ## P < 0.01 (compared with 0.8 μg/mL FMDV 146S), ˝ P < 0.05,
˝˝ P < 0.01 (compared with 4.0 μg/mL FMDV 146S).

Production of chemokines and interleukins in
FMDV 146S antigen-stimulated RMMVECs
To further investigate the influence of the
FMDV 146S antigen on the production of immuneassociated factors by RMMVECs, we assayed
the secretion of MCP-1 (CCL2), IL-6, and IL1β by ELISA. As shown in Figure 1, RMMVECs
constitutively produced MCP-1 (CCL2) at a low
level; its production persistently increased with time
from 3 h to 72 h, and the stimulation of FMDV 146S
antigen significantly enhanced its production in a
dose-dependent manner. The basal secretion of IL-6
and IL-1β was low and was also significantly elevated
by FMDV 146S antigen, similar to its influence on

MCP-1 (CCL2) production (Figure 1). However, the
secreting dynamics of IL-6 and IL-1β were different
from that of MCP-1 (CCL2), and the concentrations
of IL-6 and IL-1β, respectively, reached their peaks at
24 h and 6 h.
Expression of VCAM-1 in RMMVECs after
exposure to FMDV 146S antigen
VCAM-1 was the only classical adhesion molecule
whose mRNA expression was altered in microarray
analysis. By immunocytochemical staining, we
assayed VCAM-1 protein expression in RMMVECs
stimulated with the FMDV 146S antigen. The result
showed that the expression of VCAM-1 was weakly
positive in normal RMMVECs, and the light brown
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staining was presented within the cytoplasm and
cell membrane, but not within cell nuclei (Figure
2A). FMDV 146S-stimulated RMMVECs were more
strongly positive for VCAM-1 (Figure 2B), with
brownish-yellow marks within the cytoplasm and
cell membrane, and the negative control slip had no
positive staining (Figure 2C). In a word, the FMDV
146S antigen could up-regulate VCAM-1 expression
both at the transcription level and at the translation
level.
Discussion
MVECs are a highly heterogeneous population of
cells with the ability to interact with and modulate
the function of immune cells (3). To comprehensively
understand the immunoreactive mechanism of FMD
vaccine antigens, it was essential to investigate the
response of MVECs to them and to explore the
potential role of MVECs. The intact 146S particles are
the major immunogenic component of conventional
FMD vaccines, whose degradation greatly reduces the
potency of the vaccines (1), and whose concentration
measurement is the single most useful parameter
for the formulation of effective FMD vaccines (2).
Therefore, the FMDV 146S antigen was used in our
experiments, and its concentration and its exposure
period in microarray analysis were based an earlier
study demonstrating that they provided optimal
transcription.
By microarray analysis, we found that many
immune-associated genes were changed by the
stimulation of the FMDV 146S antigen. Although

heterogeneity exists in MVECs from various species
or different organs, their general response to the same
stimulus should be similar. Consequently, the results
obtained from RMMVECs can reflect the reaction of
MVECs of susceptible animals to the FMDV 146S
antigen, which indicates that the functional changes of
MVECs are related to immune response. Interestingly,
only 18 genes and 67 genes, among a total of 15,000
genes checked in the RMMVECs, were significantly
altered by FMDV 146S antigen stimulation for 6 h
and 24 h. The numbers of differentially expressed
genes were relatively few, which suggests that the gene
expression profile response to FMDV 146S antigen
stimulation is specific and relatively well defined.
Among the differentially up-regulated genes at 6
h and 24 h, chemokine genes are particularly worth
noticing, as their members were the most numerous
and their gene changes were significant. Chemokines
are a large cytokine family regulating leukocyte
trafficking and activation and include 4 subgroups,
whose functions are different. In our microarray
analysis, the up-regulated chemokine genes
belonged to the CC subgroup and CXC subgroup.
The CXC chemokines are primarily in attraction
of neutrophils, while the CC chemokines have
powerful chemoattractant and activator properties
for monocytes and T cells (17,18), as well as probably
for dendritic cells (DCs) and NK cells (19). At 6
h, the up-regulated chemokine genes included
4 CXC subgroup members and 1 CC subgroup
member, while at 24 h, there were 4 CXC subgroup
members and 6 CC subgroup members up-regulated.
Alternatively, as the stimulation time was prolonged,

Figure 2. Up-regulated expression of VCAM-1 in RMMVECs by FDMV 146S antigen stimulation. RMMVECs were incubated with 20
μg/mL FMDV 146S antigen for 24 h and fixed with 95% ethanol for streptavidin-peroxidase immunocytochemical staining. A)
VCAM-1 expressed constitutively at a low level in RMMVECs, B) expression of VCAM-1 in FMDV 146S antigen-stimulated
RMMVECs was strongly positive, C) negative control was not stained. Scale bar = 50 μm.
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the predominant chemokine subgroups were shifted
from the CXC subgroup to the CC subgroup, which
may indicate that the roles of MVECs shift from
regulating nonspecific immunity to regulating
specific immunity. In addition, among the CC
chemokines, monocyte inflammatory protein-3α
(MIP-3α, CCL20) was up-regulated at 6 h and 24 h,
while MIP-3β (CCL19) expression was not changed.
It was reported that MIP-3α plays an important
role in the recruitment of immature DCs, and that
MIP-3β is important to the accumulation of antigenloaded mature DCs (20).
IL-6 and IL-1 were up-regulated interleukin genes
in our microarray analysis, whose protein secretion
was proved to be enhanced by the FMDV 146S antigen
in a dose-dependent manner. IL-6 is traditionally
considered a proinflammatory cytokine; however, its
immune activities, such as resolving innate immunity
and promoting acquired immune responses (21), are
increasingly drawing attention. In vivo studies have
documented that the FMD vaccine could induce the
elevation of IL-6 production in vaccinated animals
(22,23), which is supported at the cellular level by
our data. It was reported that ectogenic IL-1 could
increase the immune response to the FMDV antigen
(24). Our data show that the FMDV 146S antigen
increases the secretion of IL-1 by RMMVECs, which
is helpful to the FMD immunity. On the other hand,
as a potent proinflammatory cytokine, the upregulation of IL-1 will have the potential of provoking
inflammatory injury.

Compared to the up-regulated genes, the downregulated genes in RMMVECs stimulated with the
FMDV 146S antigen were few. The altered genes
included no down-regulated genes at 6 h, and 7 downregulated genes at 24 h. Transforming growth factor
beta-3 (TGF-β3) was one potent immunosuppressive
factor (25) whose gene expression was down-regulated
by FMDV 146S antigen stimulation. However, little
is known regarding the functions of other downregulated genes, and the biological significance of
their down-regulation requires further investigation.
In summary, we examined the general gene
expression changes in RMMVECs after exposure
to the FMDV 146S antigen and brought forth a
new idea to understand the immunity of the FMD
vaccine antigen at the fundamental level. Our
findings show that many altered genes in FMDV
146S antigen-induced RMMVECs are associated
with immune responses, which suggests that MVECs
play an important immunomodulatory role in how
the immune system, particularly the innate immune
system, responds to the FMD vaccine.
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